Press Releases

Mar 26, 2026

Hana Yamamoto

Press Releases

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Ltd. announced robust Phase 2 clinical trial results for its SkinJect immuno-oncology product targeting basal cell carcinoma, achieving an 80% overall response rate in the 200µg cohort at Day 57. The company also detailed plans to implement an agentic AI-enabled platform to optimize drug development. Highlights include presentation b…

MDCX

Mar 26, 2026

Nina Shah

Press Releases

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

Wave Life Sciences announces encouraging 6-month data from the Phase 1 portion of its INLIGHT trial evaluating WVE-007, an investigational RNAi therapeutic for obesity. A single 240 mg dose demonstrated significant reductions in visceral fat and waist circumference, preservation of lean muscle, and a favorable safety profile. These results surpass …

WVE

Mar 26, 2026

Nina Shah

Press Releases

Bridger Aerospace Names Justin Mogford as General Counsel, Further Strengthening Management Team

Bridger Aerospace Group Holdings, a leading U.S. aerial firefighting company, announced the appointment of Justin Mogford as General Counsel and Corporate Secretary, replacing James Muchmore. Mogford brings extensive public company legal experience from Bristow Group, including expertise in aviation, corporate governance, and strategic transactions…

BAER

Mar 26, 2026

Hana Yamamoto

Press Releases

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics reports year-end 2025 financial results and significant clinical updates, including completion of enrollment in a Phase 2 Alzheimer's study, positive Phase 2 data in dementia with Lewy bodies (DLB) psychosis, initiation of an expanded access program, and plans for a mid-2026 FDA meeting to align on registrational trials for z…

CGTX

Mar 26, 2026

Priya Menon

Press Releases

Luana Savings Bank Selects nCino to Unify and Transform Its Commercial and Agricultural Lending Operations

nCino, a leading provider of intelligent banking solutions, announced that Luana Savings Bank, a well-established community bank in Iowa, has selected nCino's platform to transform and unify its commercial and agricultural lending processes. The partnership aims to replace manual, redundant tasks with automated, streamlined workflows to improve ope…

NCNO

Mar 26, 2026

Ajmal Hussain

Press Releases

Hillman Recognized by REDI Cincinnati with James A. Wuenker Growth Award for Forest Fair Mall Redevelopment Project

Hillman Solutions Corp., a leading provider of hardware-related products, has been awarded the 2026 James A. Wuenker Growth Award by REDI Cincinnati in recognition of its redevelopment project at the Forest Fair Mall site. The project consolidates several Cincinnati-area operations into a new 715,000-square-foot facility, aiming to boost collaborat…

HLMN

Mar 26, 2026

Derek Hwang

Press Releases

BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

BrainsWay Ltd. announced the completion of an additional $6 million milestone-based convertible loan investment in Neurolief Ltd., triggered by the FDA Premarket Approval of Neurolief's Proliv™Rx device for major depressive disorder (MDD). This investment follows BrainsWay's August 2025 strategic partnership with Neurolief aimed at expanding innova…

BWAY

Mar 26, 2026

Sofia Navarro

Press Releases

RVYL Shareholder Meeting Continued to April 1, with 99% of Votes Cast in Favor of Roundtable Merger

RYVYL Inc. announced that 99% of votes cast at its Special Shareholder Meeting support the planned merger with RTB Digital, Inc. The company needs just an additional 5% vote to exceed 50% of outstanding shares to complete the merger. The meeting was adjourned and will reconvene virtually on April 1, 2026, to finalize votes and merger approval. The …

RVYL

Mar 26, 2026

Sofia Navarro

Press Releases

The Lovesac Company Expands Share Repurchase Authorization by $40 Million

The Lovesac Company announced an expansion of its share repurchase authorization by $40 million, increasing the total buyback program to approximately $54.1 million. The initiative demonstrates the company's confidence in its growth prospects and financial health, supported by a strong balance sheet and credit facility. The buybacks will be funded …

LOVE

Mar 26, 2026

Jordan Park

Press Releases

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio announced its plans to initiate Phase 3 clinical trials of verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) starting Q1 2027, following positive Phase 2 trial results that showed significant efficacy improvements. The company reported strong top-line data from the VALIANT trial in severe asthma and reinf…

UPB

Mar 26, 2026

Sofia Navarro

Press Releases

USA Rare Earth Achieves Major Operational and Strategic Milestone with Commissioning of Phase 1a Magnet Production at Stillwater Facility

USA Rare Earth (USAR) has successfully commissioned its commercial magnet production line at the Stillwater, Oklahoma facility, enabling shipment of sintered neodymium-iron-boron permanent magnets starting in Q2 2026. The company expects to ramp Phase 1a capacity to 600 metric tons per annum by Q4 2026 and reach 1,200 mtpa with Phase 1b by Q1 2027,…

USAR

Mar 26, 2026

Derek Hwang

Press Releases

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Gain Therapeutics reported its financial results for Q4 and full-year 2025, highlighting significant progress with its lead drug candidate GT-02287 for Parkinson's disease. Positive Phase 1b clinical data indicates disease-modifying potential, with stable clinical scores and biomarker improvements. The company plans to initiate Phase 2 trials in th…

GANX

Mar 26, 2026

Avery Klein

Press Releases

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

HOOKIPA Pharma announced the completion of the sale of its immuno-oncology assets, including the HB-200 and HB-700 development programs, to NeoTrail Therapeutics. The transaction closes the sale agreement signed in January 2026. HB-200 and HB-700 are investigational immunotherapies targeting HPV16 positive cancers and KRAS-mutated cancers respectiv…

HOOK

Mar 26, 2026

Avery Klein

Press Releases

The Lovesac Company Reports Fourth Quarter and Fiscal 2026 Financial Results

The Lovesac Company (NASDAQ: LOVE) announced financial results for fiscal 2026 with net sales increasing modestly by 2.4% to $697.1 million. Despite revenue growth driven by showroom expansion and slight comps rise, the company experienced decreases in gross profit and net income compared to fiscal 2025, impacted by increased transportation and tar…

LOVE

Mar 26, 2026

Sofia Navarro

Press Releases

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Acumen Pharmaceuticals reported financial results for 2025, highlighting progress on its lead Alzheimer's treatment candidate sabirnetug (ACU193), including anticipation of topline Phase 2 ALTITUDE-AD study results in late 2026 and expected IND filing for its Enhanced Brain Delivery program in mid-2027. The company secured $35.75 million in private…

ABOS

Mar 26, 2026

Caleb Monroe

Press Releases

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics reported strong progress in its Phase 2 clinical programs, including near-completion of enrollment for the schizophrenia ZEPHYR trial and completion of enrollment for the autism spectrum disorder IRIS trial, with topline data expected in Q3 2026. The company received FDA Fast Track designation for its Alzheimer's disease psych…

MPLT

Mar 26, 2026

Priya Menon

Press Releases

Sportradar Expands Partnership with Hard Rock Bet, Adding Official Data from the PGA TOUR and Ultimate Fighting Championship

Sportradar has deepened its multi-year partnership with Hard Rock Bet in the U.S. by integrating official PGA TOUR and Ultimate Fighting Championship data, enhancing in-play betting capabilities and offering dynamic micro markets and advanced visualizations to users. This expansion leverages Sportradar’s recent acquisition of IMG ARENA rights for P…

SRAD

Mar 26, 2026

Jordan Park

Press Releases

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Tonix Pharmaceuticals has dosed the first participant in a Phase 1 study evaluating TNX-1900, an intranasal potentiated oxytocin formulation, in healthy volunteers to assess its potential for treating migraine and craniofacial pain by inhibiting CGRP release through a novel pathway. The study uses advanced Laser Speckle Contrast Imaging (LSCI) to m…

TNXP

Mar 26, 2026

Nina Shah

Press Releases

Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit

Hyperion DeFi, Inc., the first U.S. publicly listed DeFi company on Hyperliquid, announced robust financial results for Q4 and FY 2025. The company exceeded Q4 guidance with 64% revenue growth and 87% growth in adjusted gross profit quarter-over-quarter. It operates five diversified DeFi business lines, including staking, validator commissions, yie…

HYPD

Mar 26, 2026

Sofia Navarro

Press Releases

Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

Ligand Pharmaceuticals has expanded its business development team by hiring two seasoned healthcare investors, Peter Renehan, MD and Lee Brown, and promoting Lauren Hay to Vice President of Portfolio Strategy and Investments. These hires aim to enhance Ligand's ability to source and execute royalty financing opportunities, supporting long-term valu…

LGND

Mar 26, 2026

Hana Yamamoto

Press Releases

Tilray Brands Announces Partnership with Popsicle® to Launch Popsicle Adult Beverages

Tilray Brands has announced a new licensing agreement with The Magnum Ice Cream Company to produce and distribute ready-to-drink Popsicle Hard beverages, featuring classic Popsicle flavors with 5% alcohol by volume. The product line, including Hard Cherry, Hard Orange, Hard Grape, and a seasonal Hard Firecracker flavor, targets the US adult beverag…

TLRY

Mar 26, 2026

Ajmal Hussain

Press Releases

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

Lifecore Biomedical announced two new contract development and manufacturing organization (CDMO) agreements with an existing U.S.-based biopharmaceutical customer. The agreements include a site transfer for manufacturing a currently marketed product and expansion of manufacturing to a second delivery system for an ophthalmic treatment. These deals …

LFCR

Mar 26, 2026

Avery Klein

Press Releases

WeShop Launches Founders Programme to Empower Early Community Creators in the U.K.

WeShop Holdings Limited, a US-listed social commerce platform, announced the launch of its Founders Programme in the UK. The initiative aims to empower early community creators by offering them increased referral rewards, exclusive events, and direct engagement opportunities to help grow the platform. This move is part of WeShop's strategy to accel…

WSHP

Mar 26, 2026

Priya Menon

Press Releases

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Therapeutics announced that the USPTO granted a composition of matter patent for AGMB-447, its inhaled lung-restricted ALK5 inhibitor in development for idiopathic pulmonary fibrosis (IPF). This patent protection extends in the U.S. through at least 2041, supporting the company's clinical-stage pipeline targeting fibrosis. AGMB-447 is curren…

AGMB

Mar 26, 2026

Hana Yamamoto

Press Releases

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

Kamada Ltd., a global biopharmaceutical leader in specialty plasma-derived therapies, announced FDA approval of its new plasma collection center in San Antonio, Texas. The facility can collect up to 50,000 liters of plasma annually, with expected revenues of $8-10 million at full capacity. This center will enhance Kamada's plasma collection capabil…

KMDA